Business Wire

ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million

Del

Regulatory News:

NOT FOR DISTRIBUTION IN AUSTRALIA, CANADA OR JAPAN

ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initial closing of its previously announced global offering to specified categories of investors of an aggregate of 5,374,033 new ordinary shares, comprising an offer of 4,686,106 ordinary shares in the form of American Depositary Shares, each representing one ordinary share ("ADSs"), in the United States at an offering price of $23.26 per ADS and a concurrent private placement in Europe (including France) and other countries outside of the United States and Canada of 687,927 ordinary shares at an offering price of €20.00 per ordinary share. In addition, the underwriters for the global offering have exercised in full their option to purchase at the same price 702,915 additional ADSs and 103,189 additional ordinary shares in the global offering, with the additional closing expected to occur on November 16, 2017. Following the additional closing, aggregate net proceeds to ERYTECH, after deducting underwriting commissions and estimated offering expenses payable by ERYTECH, will be approximately $130 million. All of the securities sold in the global offering were offered by ERYTECH.

ERYTECH's ordinary shares are listed on Euronext Paris under the ticker symbol "ERYP". As of November 10, 2017, ERYTECH’s ADSs are listed on the Nasdaq Global Select Market under the ticker symbol "ERYP".

Jefferies LLC acted as global coordinator and joint book-runner for the global offering. Cowen and Company, LLC acted as joint book-runner and JMP Securities LLC acted as lead manager for the offering of ADSs in the United States. ODDO BHF SCA acted as joint book-runner for the private placement of ERYTECH’s ordinary shares in Europe.

In accordance with Article 6 of delegated regulation EU 2016/1052 of March 8, 2016, Jefferies LLC, acting as the stabilizing agent on its own behalf and on behalf of the other underwriters, reported that no stabilization activities had been carried out since November 10, 2017. The stabilization period is now closed.

The global offering was made only by means of a prospectus. A copy of the prospectus relating to the global offering was filed with the U.S. Securities and Exchange Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806.

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About ERYTECH

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.

The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP). ERYTECH is also listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Disclaimer

This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to solicit the interest of the public in France, the United States, or in any other jurisdiction, in connection with any offer.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

This announcement is not an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the "Prospectus Directive").

With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any relevant member State except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.

This document does not constitute an offer to the public in France and the securities referred to in this document can only be offered or sold in France pursuant to article L. 411-2-II of the French Monetary and Financial Code to (i) providers of third party portfolio management investment services, (ii) qualified investors (investisseurs qualifiés) acting for their own account and/or (iii) a limited group of investors (cercle restreint d’investisseurs) acting for their own account, all as defined in and in accordance with articles L. 411-1, L. 411-2 and D. 411-1 to D. 411-4 and D. 754-1 and D. 764-1 of the French Monetary and Financial Code.

This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This document does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States or any other jurisdiction where such offer may be restricted. The securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or an applicable exemption from registration requirements under the Securities Act.

Contact information

ERYTECH
Naomi Eichenbaum
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
or
The Ruth Group
Lee Roth, +1 646 536 7012
Investor relations
lroth@theruthgroup.com
or
Kirsten Thomas
Media relations, +1 508 280 6592
kthomas@theruthgroup.com
or
NewCap
Julien Perez
Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease  23.5.2018 07:00Pressemelding

For media excluding US/Canada and UK This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005102/en/ Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.1,2,3 Activity-related breathlessness is a characteristic feature of COPD.5 It limits patients’ exercise tolerance and has an impact on their daily activities, which can lead to a downward spiral of exercise avoidance and physical decline.5,6 Decreased activity results in patients experiencing further breathlessness during even lower levels of physical activity, leading to further worsening of their condition, and increasing the risk of d

eLichens Raises EUR 7 Million to Boost its Growth in France and Internationally23.5.2018 06:00Pressemelding

Designer of patented gas sensors and the first comprehensive air quality analysis and prediction platform, eLichens today announced a new EUR 7 million capital increase with its historical investors and two new entrants. This operation, which follows the success of the first raising of capital of over 4 million euros in July 2016, aims to market large volumes of its micro gas sensors to serve the needs of its industrial customers as well as the large-scale deployment of its platform that performs intelligent indoor and outdoor air quality analysis for the smart city, smart home and smart building markets. The eLichens team relies on patented technologies developed jointly with renowned laboratories such as CEA-Leti and MIT. In addition to the renewed and strengthened support from current shareholders, including DEMETER, SOFIMAC Innovation, Business Angels networks (members of France Angels) and Aereco, eLichens is delighted to welcome the Fonds Ville de Demain managed by Bpifrance as p

Greenbird Named a Gartner Cool Vendor in Application Architecture, Infrastructure and Integration23.5.2018 05:05Pressemelding

Greenbird, the company delivering Metercloud to accelerate the energy revolution, today announced that it has been named a Gartner “Cool Vendor” in Application Architecture, Infrastructure and Integration. Greenbird empowers utilities by delivering Metercloud to manage the data flow faster and smoother than traditional system integration models. With prebuilt Metercloud integration applications and connectors, software solutions can be connected and updated in a few days instead of months of custom coding. Every year Gartner identifies Cool Vendors with innovative offerings for application leaders responsible for architecture, infrastructure and integration. Thorsten Heller, CEO and Co-Founder at Greenbird, said that “In the Cool Vendor report, Gartner recommends ‘application leaders responsible for modernizing application architecture, infrastructure and integration should exploit service mesh capabilities in portable, resilient and incrementally extensible microservices implementatio

Hilton Commits to Cutting Environmental Footprint in Half and Doubling Social Impact Investment23.5.2018 04:01Pressemelding

Hilton today announced it will cut its environmental footprint in half and double its social impact investment by 2030. With this commitment, Hilton will become the first major hotel company to institute science-based targets to reduce carbon emissions and send zero soap to landfill. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006472/en/ Hilton Commits to Cutting Environmental Footprint in Half and Doubling Social Impact Investment (Photo: Business Wire) The company will also double the amount it spends with local and minority-owned suppliers, and double its investment in programs to help women and youth around the world. These goals are part of Hilton’s Travel with Purpose corporate responsibility strategy to further the United Nation’s 2030 Sustainable Development Agenda. New consumer research reaffirms Hilton’s corporate responsibility strategy. According to a survey of 72,000 Hilton guests, social, environmental

General Cable Responds to Speculation Regarding Alleged Investigation23.5.2018 03:05Pressemelding

General Cable Corporation (NYSE: BGC) (“General Cable” or “the Company”) today issued the following statement in response to a recent press report about an alleged new investigation by the United States Department of Justice (DOJ): We are aware of a recent press report regarding an alleged new DOJ investigation under the United States Foreign Corrupt Practices Act (FCPA) involving General Cable. To the best of our knowledge, we have been and remain in compliance with the terms of our December 2016 Non-Prosecution Agreement (NPA) entered into with the DOJ. We periodically communicate with the DOJ as required by the NPA, and we are not aware of any new DOJ enforcement action or investigation against the Company at this time. Cautionary Statement Regarding Forward-Looking Statements Certain statements in this communication, including, without limitation, statements regarding the Company’s compliance with the NPA and any enforcement action or investigation against the Company, and manageme

Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial22.5.2018 17:19Pressemelding

Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006139/en/ Zephyr Endobronchial Valves (Photo: Business Wire) “The LIBERATE Study definitively proves that Zephyr Valves offer clinically meaningful improvements in three important areas for patients – the ability to breathe better, be more active, and enjoy an improved quality of life,” said the study’s lead investigator, Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. He continued, “All primary and secondary endpoints were met, with Zephyr Valve treatment showing significant improvement for patients across multiple measures of breathing a